Patents by Inventor Simone Wengner
Simone Wengner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220362160Abstract: The present invention is directed to an immediate release and extended release capsule or capsule fill which mitigates the abuse of abuse-susceptible active pharmaceutical ingredients by direct intravenous injection. The fill comprises a parenteral abuse resistant liquid formulation which when mixed with water and heated, results in a turbid, viscous or bubbling mixture that is not injectable with a standard insulin syringe. The abuse-susceptible active pharmaceutical ingredient is selected from the group consisting of opiates, opioids, tranquillizers, stimulants and narcotics.Type: ApplicationFiled: July 19, 2022Publication date: November 17, 2022Applicant: R.P. Scherer Technologies, LLCInventor: Simone Wengner
-
Patent number: 11464747Abstract: The present invention is directed to an immediate release and extended release capsule or capsule fill which mitigates the abuse of abuse-susceptible active pharmaceutical ingredients by direct intravenous injection. The fill comprises a parenteral abuse resistant liquid formulation which when mixed with water and heated, results in a turbid, viscous or bubbling mixture that is not injectable with a standard insulin syringe. The abuse-susceptible active pharmaceutical ingredient is selected from the group consisting of opiates, opioids, tranquilizers, stimulants and narcotics.Type: GrantFiled: September 16, 2019Date of Patent: October 11, 2022Assignee: R.P. Scherer Technologies, LLCInventor: Simone Wengner
-
Patent number: 10744097Abstract: The present invention is directed to an immediate release and extended release capsule or capsule fill which mitigates the abuse of abuse-susceptible active pharmaceutical ingredients by direct intravenous injection. The fill comprises a parenteral abuse resistant liquid formulation which when mixed with water and heated, results in a turbid, viscous or bubbling mixture that is not injectable with a standard insulin syringe. The abuse-susceptible active pharmaceutical ingredient is selected from the group consisting of opiates, opioids, tranquillizers, stimulants and narcotics.Type: GrantFiled: September 6, 2016Date of Patent: August 18, 2020Assignee: R.P. Scherer Technologies, LLCInventor: Simone Wengner
-
Publication number: 20200009064Abstract: The present invention is directed to an immediate release and extended release capsule or capsule fill which mitigates the abuse of abuse-susceptible active pharmaceutical ingredients by direct intravenous injection. The fill comprises a parenteral abuse resistant liquid formulation which when mixed with water and heated, results in a turbid, viscous or bubbling mixture that is not injectable with a standard insulin syringe. The abuse-susceptible active pharmaceutical ingredient is selected from the group consisting of opiates, opioids, tranquilizers, stimulants and narcotics.Type: ApplicationFiled: September 16, 2019Publication date: January 9, 2020Applicant: R.P. Scherer Technologies, LLCInventor: Simone Wengner
-
Patent number: 10420729Abstract: The present invention is directed to an immediate release and extended release capsule or capsule fill which mitigates the abuse of abuse-susceptible active pharmaceutical ingredients by direct intravenous injection. The fill comprises a parenteral abuse resistant liquid formulation which when mixed with water and heated, results in a turbid, viscous or bubbling mixture that is not injectable with a standard insulin syringe. The abuse-susceptible active pharmaceutical ingredient is selected from the group consisting of opiates, opioids, tranquilizers, stimulants and narcotics.Type: GrantFiled: March 11, 2014Date of Patent: September 24, 2019Assignee: R.P. Scherer Technologies, LLCInventor: Simone Wengner
-
Patent number: 9913814Abstract: The invention is directed to an immediate release capsule which mitigates the abuse of Tapentadol or physiologically acceptable salt thereof by direct intravenous injection. The capsule comprises a tamper resistant formulation which when mixed with water and heated, results in a turbid, bubbling mixture that is not injectable with a standard insulin syringe.Type: GrantFiled: September 7, 2016Date of Patent: March 13, 2018Assignee: GRÜNENTHAL GMBHInventors: Ingo Friedrich, Richard Fuhrherr, Silke Möschter, Simone Wengner
-
Publication number: 20160374965Abstract: The invention is directed to an immediate release capsule which mitigates the abuse of Tapentadol or physiologically acceptable salt thereof by direct intravenous injection. The capsule comprises a tamper resistant formulation which when mixed with water and heated, results in a turbid, bubbling mixture that is not injectable with a standard insulin syringe.Type: ApplicationFiled: September 7, 2016Publication date: December 29, 2016Applicant: GRÜNENTHAL GMBHInventors: Ingo FRIEDRICH, Richard FUHRHERR, Silke MÖSCHTER, Simone WENGNER
-
Publication number: 20160374948Abstract: The present invention is directed to an immediate release and extended release capsule or capsule fill which mitigates the abuse of abuse-susceptible active pharmaceutical ingredients by direct intravenous injection. The fill comprises a parenteral abuse resistant liquid formulation which when mixed with water and heated, results in a turbid, viscous or bubbling mixture that is not injectable with a standard insulin syringe. The abuse-susceptible active pharmaceutical ingredient is selected from the group consisting of opiates, opioids, tranquillizers, stimulants and narcotics.Type: ApplicationFiled: September 6, 2016Publication date: December 29, 2016Applicant: R.P. Scherer Technologies, LLCInventor: Simone Wengner
-
Publication number: 20150320690Abstract: The invention is directed to an immediate release capsule which mitigates the abuse of Tapentadol or physiologically acceptable salt thereof by direct intravenous injection. The capsule comprises a tamper resistant formulation which when mixed with water and heated, results in a turbid, bubbling mixture that is not injectable with a standard insulin syringe.Type: ApplicationFiled: May 11, 2015Publication date: November 12, 2015Applicant: GRÜNENTHAL GMBHInventors: Ingo FRIEDRICH, Richard FUHRHERR, Silke MÖSCHTER, Simone WENGNER
-
Publication number: 20140271835Abstract: The present invention is directed to an immediate release and extended release capsule or capsule fill which mitigates the abuse of abuse-susceptible active pharmaceutical ingredients by direct intravenous injection. The fill comprises a parenteral abuse resistant liquid formulation which when mixed with water and heated, results in a turbid, viscous or bubbling mixture that is not injectable with a standard insulin syringe. The abuse-susceptible active pharmaceutical ingredient is selected from the group consisting of opiates, opioids, tranquillizers, stimulants and narcotics.Type: ApplicationFiled: March 11, 2014Publication date: September 18, 2014Inventor: Simone Wengner